STOCK TITAN

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced a conference call and webcast on November 8, 2022, at 5:00 p.m. ET to discuss its Q3 2022 financial results. The press release will be available after U.S. market close on the same day. Arcutis specializes in developing innovative therapies for immune-mediated dermatological diseases, utilizing a robust development platform with multiple clinical programs targeting conditions like scalp psoriasis and atopic dermatitis. For more details, visit www.arcutis.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 32,300 restricted stock units and options for 85,800 shares to nine new employees, as approved by its Compensation Committee. These awards were made under the 2022 Inducement Plan, with the grant date set on September 1, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term and an exercise price of $19.20 per share, equal to the closing price on October 3, 2022. This initiative aims to attract key talent as part of Arcutis’ ongoing growth in immuno-dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
Rhea-AI Summary

Arcutis Biotherapeutics announced positive results from the Phase 3 ARRECTOR trial of roflumilast foam 0.3% for scalp and body psoriasis. The study met both co-primary endpoints: 67.3% of participants achieved S-IGA Success versus 28.1% with a vehicle, while 46.5% achieved B-IGA Success compared to 20.8%. Roflumilast foam demonstrated a favorable safety profile, with a majority completing the trial. Arcutis plans to file a New Drug Application based on these results, highlighting the foam's potential to address unmet needs in psoriasis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced positive results from two pivotal Phase 3 studies published in JAMA, evaluating its roflumilast cream for chronic plaque psoriasis treatment. In these studies, 40% of treated patients achieved Investigator Global Assessment success at eight weeks, significantly outperforming the vehicle group. Key findings include around 70% achieving intertriginous-IGA success and approximately 40% reaching PASI-75. Roflumilast showed rapid improvements in itch and plaque clearance, with a favorable safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics has announced positive data from the STRATUM Phase 3 trial of its investigational roflumilast foam for treating seborrheic dermatitis in adults and children 9 and older. The study achieved its primary endpoint, with 80.1% of patients achieving 'IGA Success' compared to 59.2% with vehicle (P<0.0001). Over 60% experienced significant itch relief by week 8. All secondary endpoints also showed statistically significant improvements. Roflumilast foam was well-tolerated, showing no serious adverse events, and an NDA submission is planned for Q1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
Rhea-AI Summary

LifeArc today announced the acquisition of its portfolio company Ducentis BioTherapeutics by Arcutis Biotherapeutics (NASDAQ: ARQT) for up to $400 million. The deal includes a $16 million upfront cash payment and Arcutis stock valued at $14 million, plus contingent payments linked to development success. Ducentis' lead asset, DS-234, targets the underserved atopic dermatitis market.

Arcutis aims to leverage its expertise in dermatology to accelerate the clinical development of DS-234, enhancing its innovative treatment pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
-
Rhea-AI Summary

Arcutis announced the acquisition of Ducentis BioTherapeutics for approximately $30 million in cash and stock, targeting the development of DS-234, a promising treatment for atopic dermatitis. The growing market shows a significant unmet need, and DS-234 aims to be a best-in-class option, complementing Arcutis’ existing therapies. The acquisition leverages Arcutis’ dermatology expertise, with the goal of advancing innovative therapies to address critical patient needs in immune-mediated diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the presentation of four abstracts for its topical roflumilast program at the EADV Congress from September 7-10, 2022. Key highlights include the oral presentation of data from the STRATUM Phase 3 trial of roflumilast foam in seborrheic dermatitis, scheduled for September 9. The company emphasizes the unmet need for non-steroidal treatments, showcasing the safety and efficacy of ZORYVE (roflumilast cream) for plaque psoriasis. This initiative underscores Arcutis' commitment to addressing dermatological conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.57%
Tags
none
Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 96,500 restricted stock units and options for 212,500 shares to 39 new employees as part of its 2022 Inducement Plan. These awards, approved by the Compensation Committee, were granted on September 1, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $26.87 per share. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract top talent amid Arcutis' focus on immuno-dermatology innovations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.57%
Tags
none

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $13.63 as of January 13, 2025.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.6B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

ARQT Stock Data

1.62B
104.31M
1.93%
113.6%
19.75%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE